Status:
RECRUITING
The Effectiveness of Bu Zhong Yi Qi Tang in Patients with Myasthenia Gravis
Lead Sponsor:
Cheng, yu-ting
Conditions:
Myasthenia Gravis
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
Research Background: According to the Myasthenia Gravis Foundation of America (MGFA, 2015), the estimated prevalence of myasthenia gravis is 14-20 per 100,000 people, with a higher prevalence in young...
Detailed Description
:This study aims to assess the effectiveness of using a combination of traditional Chinese and Western medicine,to improve the meridian energy and autonomic nervous system function of myasthenia gravi...
Eligibility Criteria
Inclusion
- Patients diagnosed with ocular myasthenia by a doctor
- Western medicine prescriptions only take oral Mestinon (Pyrido stigmine Bromide)
- Patients over 20 years old
- Can understand and understand Those who can speak Mandarin or Taiwanese
- those with a clear state of consciousness and no diagnosis of mental illness
- patients and their families who are willing to receive precise integrated treatment of traditional Chinese and Western medicine.
Exclusion
- Patients with liver failure or kidney failure
- Allergy symptoms to traditional Chinese medicine, such as skin itching and redness
- Patients with malignant tumors
- Patients currently undergoing radiotherapy and chemotherapy
- Pregnant
- Cardiac rhythm device implementer
Key Trial Info
Start Date :
June 14 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 13 2025
Estimated Enrollment :
112 Patients enrolled
Trial Details
Trial ID
NCT06881173
Start Date
June 14 2022
End Date
June 13 2025
Last Update
March 20 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shin Kong Wu Ho-Su Memorial Hospital
Taipei, Taiwan